01 · 2020s
Retatrutide
Eli Lilly, USA
Triple GIP/GLP-1/glucagon agonist in late-stage development.
Open the individual record →Seeking Canonization
Active petitions: promising, unfinished, and not FDA-approved
02 · 2020s
Cagrilintide
Novo Nordisk, Denmark
Long-acting amylin analog studied alone and with semaglutide; not FDA-approved.
Open the individual record →
03 · 2020s
Survodutide
Boehringer Ingelheim + Zealand Pharma
Dual glucagon/GLP-1 agonist in clinical development; not FDA-approved.
Open the individual record →
04 · 2020s
Petrelintide
Zealand Pharma + Roche
Investigational amylin analogue for weight management. Phase 3 program underway; not FDA-approved.
Open the individual record →